The novel triple reuptake inhibitor JZAD-IV-22 exhibits an antidepressant pharmacological profile without locomotor stimulant or sensitization properties
Barbara J. Caldarone, Neil E. Paterson, Jia Zhou, Daniela Brunner, Alan P. Kozikowski, Koen G.C. Westphal, Gerdien A.H. Korte-Bouws, Jolanda Prins, S. Mechiel Korte, Berend Olivier, Afshin Ghavami
Research output: Contribution to journal › Article › peer-review
Dive into the research topics of 'The novel triple reuptake inhibitor JZAD-IV-22 exhibits an antidepressant pharmacological profile without locomotor stimulant or sensitization properties'. Together they form a unique fingerprint.